老年晚期非小细胞肺癌个体化治疗临床分析  

Individualized therapy of advanced non-small cell lung cancer in the elderly

作　　者：赫丽杰[1] 李莉[1] 闫红艳[1] 

机构地区：[1]辽宁省丹东市中心医院肿瘤科,118002

出　　处：《中国肿瘤临床与康复》2008年第1期33-37,共5页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的分析老年非小细胞肺癌个体化治疗方式。方法将我院1995年1月至2005年1月收治的有完整资料98例(年龄≥60岁)老年非小细胞肺癌患者分为单药化疗组、铂类为基础的联合化疗和非铂类的联合化疗三组,对其临床资料及治疗效果进行回顾性对照分析。结果单药化疗组21例,铂类为基础的联合化疗64例,非铂类的联合化疗组13例。单药化疗组心、肝、肾等基础疾病合并率(100.0%)明显高于其他两组(P=0.01)。铂类联合化疗组有效率(39.1%)与非铂类联合化疗组(38.5%)差异无显著性,但明显高于单药化疗组(23.8%);但铂类联合化疗组CR(12.5%)明显高于其他两组(P=0.04)。铂类联合化疗组中位生存期(MST)11个月,疾病进展时间(TTP)7个月,1年生存率37.5%,2年生存率18.8%,均显著高于其他两组(P<0.05)。铂类联合化疗组Ⅲ～Ⅳ度副反应发生率及平均每次住院天数(40d)与非铂类联合化疗组差异无显著性(P>0.05),但明显高于单药化疗组(P<0.05)。结论高龄并非化疗禁忌,一般情况良好的老年非小细胞肺癌应行铂类为基础的联合化疗,一般情况较差者,可行单药化疗。Objective To analyze individualized therapy mode for advanced non-small cell lung cancer（NSCLC） in the elderly. Methods Ninty-eight patients aged≥60 with advanced NSCLC lung cancer admitted to this hospital from Jan 1995 to Jan 2005 were divided into three groups ：single agent chemotherapy group, combined chemotherapy based on platinum and combined chemotherapy without platinum. The clinical characteristics and treatment efficacy were reviewed and compared. Results There were 21 cases in the single agent chemotherapy group ,64 cases in the combined chemotherapy based on platinum group, 13 cases in the combined chemotherapy without platinum group. The underlying severe diseases rate（ 100% ） in the single agent group was significantly higher than that in the other two groups（ P = 0.01 ）. The response rate（RR） of combined chemotherapy with platinum group （39.1% ） was not significantly different from the combined chemotherapy without platinum group （38.5%） , but it was significantly higher than that in the single agent chemotherapy group（23.8% ）. The complete response rate（CR） of the combined chemotherapy with platinum group （ 12.5 % ） was markedly higher than that of the other two groups （P = 0.04）. The median survival time（MST） （11 months）,to treatment progress time（TIP） （7 months）,one-year survival rate（37.5% ） and 2-year survival rate（ 18.8% ） of the combined chemotherapy with platinum group were significantly higher than those of the other two groups （ P 〈 0.05 ）. The Ⅲ- Ⅳ-degree side effects and mean hospitalization days each time（40 days）in combined chemotherapy with platinum group had no significant difference from the combined chemotherapy without platinum group （P 〉 0.05 ）. Conclusion The elderly advanced NSCLC patients with good general condition can receive combined chemotherapy based on platinum, while the patients with poor general condition can receive single agent chemotherapy.

关 键 词：老年 肺肿瘤/治疗学 个体化 

分 类 号：R734.2[医药卫生—肿瘤] R730.5[医药卫生—临床医学]